S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
OTCMKTS:IPCIF

Intellipharmaceutics International News Headlines

$0.17
+0.04 (+30.94%)
(As of 01/14/2022 03:56 PM ET)
Add
Compare
Today's Range
$0.12
$0.20
50-Day Range
$0.08
$0.20
52-Week Range
$0.08
$0.48
Volume
154,400 shs
Average Volume
24,800 shs
Market Capitalization
$5.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.75
Get Intellipharmaceutics International News Delivered to You Automatically

Sign up to receive the latest news and ratings for IPCIF and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Intellipharmaceutics International Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IPCIF
News Sentiment

0.09

0.32

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IPCIF Articles
This Week

5

0

IPCIF Articles
Average Week



Intellipharmaceutics International (OTCMKTS:IPCIF) News Headlines Today

SourceHeadline
MarketBeat logoIntellipharmaceutics International Inc. (OTCMKTS:IPCIF) Sees Significant Growth in Short Interest
americanbankingnews.com - January 14 at 2:46 AM
finance.yahoo.com logoIntellipharmaceutics Mourns the Death of Valued Board Member Kenneth Eugene Keirstead
finance.yahoo.com - January 13 at 5:44 PM
MarketBeat logoIntellipharmaceutics International Inc. (OTCMKTS:IPCIF) Short Interest Update
americanbankingnews.com - January 10 at 7:38 AM
MarketBeat logoIntellipharmaceutics International (OTCMKTS:IPCIF) Shares Pass Above 200-Day Moving Average of $0.15
americanbankingnews.com - December 28 at 2:02 AM
finance.yahoo.com logoIntellipharmaceutics Comments on Recent Trading Activity
finance.yahoo.com - December 22 at 5:01 PM
finanznachrichten.de logoIntellipharmaceutics International Inc.: Intellipharmaceutics Announces Third Quarter 2021 Results
finanznachrichten.de - October 16 at 8:10 PM
businesswire.com logoKim Spencer McPhee Barristers, P.C. Publishes This Notice of Settlement Approval of the Intellipharmaceutics International Inc. Securities Class Action
businesswire.com - October 13 at 5:44 PM
finance.yahoo.com logoIntellipharmaceutics International Inc. (IPCI.TO)
finance.yahoo.com - June 17 at 11:49 PM
finance.yahoo.com logoIntellipharmaceutics Announces Closing of CAD$3.85 Million Non-Brokered Private Placement
finance.yahoo.com - April 22 at 9:25 AM
finance.yahoo.com logoGroup Nine Acquisition Corp. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing March 8, 2021
finance.yahoo.com - March 8 at 9:47 AM
markets.businessinsider.com logoNews for IntelliPharmaCeutics International Inc Registered Shs
markets.businessinsider.com - December 30 at 8:53 AM
finanznachrichten.de logoIntellipharmaceutics International Inc.: Intellipharmaceutics Reports Director Election Results
finanznachrichten.de - December 23 at 6:04 PM
finance.yahoo.com logoIntellipharmaceutics Reports Director Election Results
finance.yahoo.com - December 23 at 6:04 PM
finance.yahoo.com logoIntellipharmaceutics Announces Change in Venue for The Company’s Annual General Meeting Scheduled To Be Held on December 23, 2020
finance.yahoo.com - December 15 at 8:12 PM
finanznachrichten.de logoIntellipharmaceutics International Inc.: Intellipharmaceutics Announces Third Quarter 2020 Results
finanznachrichten.de - October 15 at 6:43 PM
finance.yahoo.com logoKahn Swick & Foti, LLC Announces Summary Notice of Proposed Settlement Involving Purchasers of Intellipharmaceutics Common Stock
finance.yahoo.com - August 17 at 2:25 PM
finance.yahoo.com logo"Intellipharmaceutics Announces That The Company And Purdue Pharma L.P. et al Have Entered Into A Stipulated Dismissal Agreement To Terminate Purdue Patent Litigation, Subject To Court Approval"
finance.yahoo.com - July 2 at 11:22 AM
www.finanznachrichten.de logoIntellipharmaceutics International Inc.: Intellipharmaceutics Announces First Quarter 2020 Results
www.finanznachrichten.de - May 29 at 6:29 PM
www.bloomberg.com logoIntellipharmaceutics Announces Receipt of Cannabis Drug License from Health Canada
www.bloomberg.com - April 27 at 8:38 AM
www.bloomberg.com logoIntellipharmaceutics Announces FDA Approval for Generic Pristiq(R)
www.bloomberg.com - April 21 at 9:51 PM
www.finanznachrichten.de logoIntellipharmaceutics International Inc.: Intellipharmaceutics Provides Timing of First Quarter 2020 Results
www.finanznachrichten.de - April 11 at 8:05 AM
finance.yahoo.com logoIntellipharmaceutics: Fiscal 4Q Earnings Snapshot
finance.yahoo.com - February 29 at 8:18 PM
finance.yahoo.com logoIntellipharmaceutics Announces Fiscal Year 2019 Results
finance.yahoo.com - February 28 at 5:25 PM
www.finanznachrichten.de logoIntellipharmaceutics International Inc.: Intellipharmaceutics Announces Resignation of Chief Financial Officer
www.finanznachrichten.de - February 5 at 7:05 PM
finance.yahoo.com logoIntellipharmaceutics Announces Resignation of Chief Financial Officer
finance.yahoo.com - February 5 at 7:05 PM
finance.yahoo.com logoIntellipharmaceutics Provides Update on FDA Advisory Committees Meeting for Aximris XR(TM) (Oxycodone Hydrochloride extended release) an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
finance.yahoo.com - January 16 at 12:50 PM
seekingalpha.com logoFDA Ad Com thumbs down on Intellipharmaceutics' oxycodone ER
seekingalpha.com - January 16 at 12:02 AM
seekingalpha.com logoIntellipharmaceutics down 13% ahead of Ad Com meeting on oxycodone ER
seekingalpha.com - January 14 at 5:02 PM
www.proactiveinvestors.com logoIntellipharmaceuticals shares rise after FDA committee schedules review of lead drug candidate Aximiris XR
www.proactiveinvestors.com - December 10 at 6:17 PM
finance.yahoo.com logoIntellipharmaceutics Announces FDA Advisory Committee Meeting for Aximris XR(TM) (Oxycodone Hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
finance.yahoo.com - December 5 at 1:34 PM
finance.yahoo.com logoIntellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc. for Venlafaxine ER
finance.yahoo.com - November 25 at 8:07 PM
finance.yahoo.com logoIntellipharmaceutics Closes USD$250,000 Convertible Debenture Financing with Drs. Isa and Amina Odidi
finance.yahoo.com - November 18 at 5:55 PM
finance.yahoo.com logoIntellipharmaceutics Update on its Oxycodone ER New Drug Application
finance.yahoo.com - October 24 at 6:13 PM
finance.yahoo.com logoIntellipharmaceutics Announces Third Quarter 2019 Results
finance.yahoo.com - October 11 at 5:42 PM
www.finanznachrichten.de logoIntellipharmaceutics International Inc.: Intellipharmaceutics Announces an Update in the Purdue Litigation
www.finanznachrichten.de - October 6 at 1:24 PM
finance.yahoo.com logoIntellipharmaceutics Signs a Second Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc.
finance.yahoo.com - September 24 at 4:49 PM
finance.yahoo.com logoIntellipharmaceutics International Inc. Announces Update on its Oxycodone ER New Drug Application
finance.yahoo.com - July 24 at 5:38 PM
www.finanznachrichten.de logoIntellipharmaceutics International Inc.: Intellipharmaceutics Announces Second Quarter 2019 Results
www.finanznachrichten.de - July 11 at 10:04 AM
finance.yahoo.com logoIntellipharmaceutics International Inc. Announces $10,000,000 Equity Financing Commitment
finance.yahoo.com - July 9 at 11:02 AM
www.finanznachrichten.de logoIntellipharmaceutics International Inc.: Intellipharmaceutics to present at the 9th Annual LD Micro Invitational
www.finanznachrichten.de - May 29 at 10:48 AM
finance.yahoo.com logoU.S. FDA Acknowledges Receipt of Intellipharmaceutics' Resubmission of Oxycodone ER New Drug Application, Deems it a Complete Response, and Designates August 28, 2019 as Goal Date for Review
finance.yahoo.com - March 29 at 12:18 PM
finance.yahoo.com logoIntellipharmaceutics Receives Nasdaq Listing Determination; To Begin Trading on the OTC Markets System
finance.yahoo.com - March 20 at 11:20 AM
finance.yahoo.com logoFour Marijuana Stocks Green and Ready for the Picking
finance.yahoo.com - March 4 at 4:12 PM
www.finanznachrichten.de logoIntellipharmaceutics International Inc.: Intellipharmaceutics Announces Resubmission of New Drug Application to the U.S. FDA for its Oxycodone ER
www.finanznachrichten.de - March 4 at 8:11 AM
finance.yahoo.com logoIntellipharmaceutics Receives Extension from Nasdaq Hearings Panel
finance.yahoo.com - January 29 at 11:19 AM
finance.yahoo.com logoIntellipharmaceutics Announces Research and Development Program for a Pipeline of Pharmaceutical Cannabidiol Based Products
finance.yahoo.com - January 7 at 10:12 AM
Get Intellipharmaceutics International News Delivered to You Automatically

Sign up to receive the latest news and ratings for IPCIF and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.